<DOC>
	<DOC>NCT00096616</DOC>
	<brief_summary>The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.</brief_summary>
	<brief_title>Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Patient greater than or equal to 18 years of age, nonsmokers, diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal, stable use of Beta agonist daily use of inhaled steroids for one year Patients with other significant diseases other than asthma, requiring oxygen, intubated within 5 years, asthma exacerbation within 6 weeks of trial, use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids, participating in another interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>